Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer: The Unmet Need for Onco-Cardiology

被引:133
作者
Al-Kindi, Sadeer G.
Oliveira, Guilherme H.
机构
[1] Univ Hosp Case Med Ctr, Oncocardiol Program, Cleveland, OH USA
[2] Univ Hosp Case Med Ctr, Adv Heart Failure & Transplant Ctr, Harrington Heart & Vasc Inst, Cleveland, OH USA
关键词
RISK-FACTORS; SURVIVAL; EVENTS; IMPACT;
D O I
10.1016/j.mayocp.2015.09.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cancer and cardiovascular diseases (CVDs) share many of the same risk factors. Using a cloud-based health care database, we identified patients with malignancies that often require cardiotoxic treatments (leukemia/lymphoma and lung, breast, colon, renal, and head and neck cancers). We report the prevalence of CVDs (coronary artery disease, carotid artery disease, peripheral vascular disease, cerebrovascular disease, and heart failure) in those populations. Overall, CVD prevalences were 33% for hematologic, 43% for lung, 17% for breast, 26% for colon, 35% for renal, and 26% for head and neck cancers. Generally, patients with lung and hematologic malignancies had the highest prevalence of all types of CVDs. Of those with CVD, only half were referred to cardiologists and received guideline-directed medical therapy. The prevalence of CVDs is unexpectedly high and suboptimally managed in patients with cancer. There seems to be an opportunity for onco-cardiologists to fulfill this unmet need and help improve outcomes in patients with cancer and coexisting heart disease. (C) 2016 Mayo Foundation for Medical Education and Research
引用
收藏
页码:81 / 83
页数:3
相关论文
共 7 条
  • [1] Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
    Herrmann, Joerg
    Lerman, Amir
    Sandhu, Nicole P.
    Villarraga, Hector R.
    Mulvagh, Sharon L.
    Kohli, Manish
    [J]. MAYO CLINIC PROCEEDINGS, 2014, 89 (09) : 1287 - 1306
  • [2] Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma
    Hershman, Dawn L.
    McBride, Russell B.
    Eisenberger, Andrew
    Tsai, Wei Yann
    Grann, Victor R.
    Jacobson, Judith S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) : 3159 - 3165
  • [3] Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine
    Jensen, SA
    Sorensen, JB
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (04) : 487 - 493
  • [4] Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data
    Kaelber, David C.
    Foster, Wendy
    Gilder, Jason
    Love, Thomas E.
    Jain, Anil K.
    [J]. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2012, 19 (06) : 965 - 972
  • [5] Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis
    Kravchenko, Julia
    Berry, Mark
    Arbeev, Konstantin
    Lyerly, H. Kim
    Yashin, Anatoly
    Akushevich, Igor
    [J]. LUNG CANCER, 2015, 88 (01) : 85 - 93
  • [6] Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients
    Oliveira, Guilherme H.
    Mukerji, Siddarth
    Hernandez, Adrian V.
    Qattan, Marwan Y.
    Banchs, Jose
    Durand, Jean-Bernard
    Iliescu, Cezar
    Plana, Juan Carlos
    Tang, W. H. Wilson
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2014, 113 (11) : 1893 - 1898
  • [7] Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival
    Wang, Shi-Yi
    Long, Jessica B.
    Hurria, Arti
    Owusu, Cynthia
    Steingart, Richard M.
    Gross, Cary P.
    Chen, Jersey
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (02) : 411 - 419